Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Dynavax reports Q2 EPS (53c), consensus (24c) » 16:21
08/06/20
08/06
16:21
08/06/20
16:21
DVAX

Dynavax

$8.82 /

-0.14 (-1.56%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DVAX Dynavax
$8.82 /

-0.14 (-1.56%)

DVAX Dynavax
$8.82 /

-0.14 (-1.56%)

08/03/20 H.C. Wainwright
Dynavax price target raised to $14 from $12 at H.C. Wainwright
07/16/20 William Blair
Dynavax has 'attractive asset' in CpG 1018, says William Blair
06/15/20 Evercore ISI
Dynavax initiated with an Outperform at Evercore ISI
05/19/20 William Blair
William Blair cautious on COVID-driven rally in Dynavax shares
DVAX Dynavax
$8.82 /

-0.14 (-1.56%)

  • 22
    May
  • 08
    Aug
DVAX Dynavax
$8.82 /

-0.14 (-1.56%)

DVAX Dynavax
$8.82 /

-0.14 (-1.56%)

Options
Dynavax call volume above normal and directionally bullish » 13:05
08/06/20
08/06
13:05
08/06/20
13:05
DVAX

Dynavax

$8.73 /

-0.23 (-2.57%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DVAX Dynavax
$8.73 /

-0.23 (-2.57%)

DVAX Dynavax
$8.73 /

-0.23 (-2.57%)

08/03/20 H.C. Wainwright
Dynavax price target raised to $14 from $12 at H.C. Wainwright
07/16/20 William Blair
Dynavax has 'attractive asset' in CpG 1018, says William Blair
06/15/20 Evercore ISI
Dynavax initiated with an Outperform at Evercore ISI
05/19/20 William Blair
William Blair cautious on COVID-driven rally in Dynavax shares
DVAX Dynavax
$8.73 /

-0.23 (-2.57%)

  • 22
    May
  • 08
    Aug
DVAX Dynavax
$8.73 /

-0.23 (-2.57%)

DVAX Dynavax
$8.73 /

-0.23 (-2.57%)

Monday
Options
Dynavax call volume above normal and directionally bullish » 13:25
08/03/20
08/03
13:25
08/03/20
13:25
DVAX

Dynavax

$8.69 /

+0.575 (+7.09%)

Bullish option flow…

Bullish option flow detected in Dynavax with 5,158 calls trading, 1.5x expected, and implied vol increasing almost 15 points to 171.90%. Aug-20 10 calls and Aug-20 7 calls are the most active options, with total volume in those strikes near 2,600 contracts. The Put/Call Ratio is 0.12. Earnings are expected on August 6th.

ShowHide Related Items >><<
DVAX Dynavax
$8.69 /

+0.575 (+7.09%)

DVAX Dynavax
$8.69 /

+0.575 (+7.09%)

08/03/20 H.C. Wainwright
Dynavax price target raised to $14 from $12 at H.C. Wainwright
07/16/20 William Blair
Dynavax has 'attractive asset' in CpG 1018, says William Blair
06/15/20 Evercore ISI
Dynavax initiated with an Outperform at Evercore ISI
05/19/20 William Blair
William Blair cautious on COVID-driven rally in Dynavax shares
DVAX Dynavax
$8.69 /

+0.575 (+7.09%)

  • 22
    May
  • 08
    Aug
DVAX Dynavax
$8.69 /

+0.575 (+7.09%)

DVAX Dynavax
$8.69 /

+0.575 (+7.09%)

Recommendations
Dynavax price target raised to $14 from $12 at H.C. Wainwright » 11:33
08/03/20
08/03
11:33
08/03/20
11:33
DVAX

Dynavax

$8.21 /

+0.1 (+1.23%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Edward White raised the firm's price target on Dynavax to $14 from $12 and keeps a Buy rating on the shares after privately-held TriSalus Life Sciences acquired Dynavax's SD-101 oncology program for a $5M upfront payment and up to an additional $250M in milestone payments and low double-digit royalties. The analyst, who notes he did not factor the SD-101 oncology program in his valuation previously, sees the monetization of this asset as a positive.

ShowHide Related Items >><<
DVAX Dynavax
$8.21 /

+0.1 (+1.23%)

DVAX Dynavax
$8.21 /

+0.1 (+1.23%)

07/16/20 William Blair
Dynavax has 'attractive asset' in CpG 1018, says William Blair
06/15/20 Evercore ISI
Dynavax initiated with an Outperform at Evercore ISI
05/19/20 William Blair
William Blair cautious on COVID-driven rally in Dynavax shares
10/18/19 H.C. Wainwright
Dynavax initiated with a Buy at H.C. Wainwright
DVAX Dynavax
$8.21 /

+0.1 (+1.23%)

  • 22
    May
  • 08
    Aug
DVAX Dynavax
$8.21 /

+0.1 (+1.23%)

DVAX Dynavax
$8.21 /

+0.1 (+1.23%)

Hot Stocks
TriSalus acquires Dynavax's SD-101 Oncology Program in purchase agreement » 08:09
08/03/20
08/03
08:09
08/03/20
08:09
DVAX

Dynavax

$8.11 /

-0.26 (-3.11%)

Dynavax Technologies and…

Dynavax Technologies and TriSalus announced that they have entered into an asset purchase agreement under which TriSalus has purchased SD-101, a proprietary investigational, second-generation, Toll-like receptor 9 agonist CpG-C class oligodeoxynucleotide, which has been studied in advanced cutaneous melanoma, and is currently in clinical trials for high risk Stage II/III breast cancer. Purchased assets include SD-101-related Intellectual Property, clinical data, regulatory filings, and inventory. Under the terms of the agreement, TriSalus will pay Dynavax $5M upfront, an additional cash payment of $4 million on December 30, 2020, for reimbursement of research and development expenses, up to an additional $250 million upon the achievement of certain development, regulatory, and commercial milestones, and low double-digit royalties based on potential future net sales.

ShowHide Related Items >><<
DVAX Dynavax
$8.11 /

-0.26 (-3.11%)

DVAX Dynavax
$8.11 /

-0.26 (-3.11%)

07/16/20 William Blair
Dynavax has 'attractive asset' in CpG 1018, says William Blair
06/15/20 Evercore ISI
Dynavax initiated with an Outperform at Evercore ISI
05/19/20 William Blair
William Blair cautious on COVID-driven rally in Dynavax shares
10/18/19 H.C. Wainwright
Dynavax initiated with a Buy at H.C. Wainwright
DVAX Dynavax
$8.11 /

-0.26 (-3.11%)

  • 22
    May
  • 08
    Aug
DVAX Dynavax
$8.11 /

-0.26 (-3.11%)

DVAX Dynavax
$8.11 /

-0.26 (-3.11%)

Over a week ago
Hot Stocks
Dynavax, Medigen collaborate to develop adjuvanted COVID-19 vaccine candidate » 08:15
07/23/20
07/23
08:15
07/23/20
08:15
DVAX

Dynavax

$10.13 /

-0.09 (-0.88%)

Dynavax Technologies and…

Dynavax Technologies and Medigen Vaccine Biologics announced their collaboration to develop an adjuvanted vaccine candidate to protect against COVID-19. The collaboration is evaluating the combination of MVC's stable prefusion form of the SARS-CoV2 recombinant spike protein with Dynavax's advanced adjuvant CpG 1018, the adjuvant contained in Dynavax's U.S. FDA-approved adult hepatitis B vaccine MVC's subunit vaccine is based on the stable prefusion form of the SARS-CoV2 recombinant spike protein with global technology license from the U.S Vaccine Research Center at National Institutes of Health. Preclinical studies demonstrated that the vaccine candidate adjuvanted with CpG 1018 generated strong immune responses in experimental animals.

ShowHide Related Items >><<
DVAX Dynavax
$10.13 /

-0.09 (-0.88%)

DVAX Dynavax
$10.13 /

-0.09 (-0.88%)

07/16/20 William Blair
Dynavax has 'attractive asset' in CpG 1018, says William Blair
06/15/20 Evercore ISI
Dynavax initiated with an Outperform at Evercore ISI
05/19/20 William Blair
William Blair cautious on COVID-driven rally in Dynavax shares
10/18/19 H.C. Wainwright
Dynavax initiated with a Buy at H.C. Wainwright
DVAX Dynavax
$10.13 /

-0.09 (-0.88%)

  • 22
    May
  • 08
    Aug
DVAX Dynavax
$10.13 /

-0.09 (-0.88%)

DVAX Dynavax
$10.13 /

-0.09 (-0.88%)

Options
Dynavax call volume above normal and directionally bullish » 11:25
07/17/20
07/17
11:25
07/17/20
11:25
DVAX

Dynavax

$11.75 /

+2.26 (+23.81%)

Bullish option flow…

Bullish option flow detected in Dynavax with 13,642 calls trading, 5x expected, and implied vol increasing over 7 points to 152.23%. Jul-20 10 calls and Jul-20 11 calls are the most active options, with total volume in those strikes near 3,800 contracts. The Put/Call Ratio is 0.11. Earnings are expected on August 5th.

ShowHide Related Items >><<
DVAX Dynavax
$11.75 /

+2.26 (+23.81%)

DVAX Dynavax
$11.75 /

+2.26 (+23.81%)

07/16/20 William Blair
Dynavax has 'attractive asset' in CpG 1018, says William Blair
06/15/20 Evercore ISI
Dynavax initiated with an Outperform at Evercore ISI
05/19/20 William Blair
William Blair cautious on COVID-driven rally in Dynavax shares
10/18/19 H.C. Wainwright
Dynavax initiated with a Buy at H.C. Wainwright
DVAX Dynavax
$11.75 /

+2.26 (+23.81%)

  • 22
    May
  • 08
    Aug
DVAX Dynavax
$11.75 /

+2.26 (+23.81%)

DVAX Dynavax
$11.75 /

+2.26 (+23.81%)

Recommendations
Dynavax has 'attractive asset' in CpG 1018, says William Blair » 15:05
07/16/20
07/16
15:05
07/16/20
15:05
DVAX

Dynavax

$9.39 /

+0.025 (+0.27%)

After Dynavax announced a…

After Dynavax announced a new collaboration with Mount Sinai to employ the company's proprietary CpG 1018 adjuvant in an effort to develop a universal influenza vaccine, William Blair analyst Matt Phipps said he views the announcement as in line with a continued focus on driving value with CpG 1018 through collaborations. The analyst, who believes its "clear mechanism of action" and extensive safety database make CpG 1018 "an attractive asset across a range of indications," keeps an Outperform rating on Dynavax shares.

ShowHide Related Items >><<
DVAX Dynavax
$9.39 /

+0.025 (+0.27%)

DVAX Dynavax
$9.39 /

+0.025 (+0.27%)

06/15/20 Evercore ISI
Dynavax initiated with an Outperform at Evercore ISI
05/19/20 William Blair
William Blair cautious on COVID-driven rally in Dynavax shares
10/18/19 H.C. Wainwright
Dynavax initiated with a Buy at H.C. Wainwright
DVAX Dynavax
$9.39 /

+0.025 (+0.27%)

  • 22
    May
  • 08
    Aug
DVAX Dynavax
$9.39 /

+0.025 (+0.27%)

DVAX Dynavax
$9.39 /

+0.025 (+0.27%)

Hot Stocks
Dynavax, Mount Sinai collaborate to develop influenza vaccine » 08:43
07/16/20
07/16
08:43
07/16/20
08:43
DVAX

Dynavax

$9.37 /

+0.18 (+1.96%)

Dynavax Technologies and…

Dynavax Technologies and the Icahn School of Medicine at Mount Sinai announced they have entered into a collaboration to develop a universal influenza vaccine. Mount Sinai's current work in this area is funded under a contract award from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH), as part of the Collaborative Influenza Vaccine Innovation Centers program established by NIAID. The Mount Sinai CIVICs team will evaluate a novel approach they have developed called chimeric hemagglutinin designed to protect against all strains of influenza in combination with Dynavax's CpG 1018TM adjuvant. The development program will support an Investigational New Drug application for Phase I clinical trials. Drs. Peter Palese, PhD, Professor and Chair of the Department of Microbiology at Mount Sinai, Adolfo-Garcia-Sastre, PhD, Director of the Global Health and Emerging Pathogens Institute, and the Irene and Dr. Arthur M. Fishberg Professor of Microbiology and Medicine at Mount Sinai, and Florian Krammer, PhD, Professor of Microbiology at Mount Sinai will be leading the development of the program. There are no approved universal flu vaccines. The effectiveness of seasonal influenza vaccine ranges between 10% and 60%. A universal vaccine could eliminate the need to update and administer the seasonal flu vaccine annually and could protect against newly emerging flu strains, potentially including those that could cause a flu pandemic.

ShowHide Related Items >><<
DVAX Dynavax
$9.37 /

+0.18 (+1.96%)

DVAX Dynavax
$9.37 /

+0.18 (+1.96%)

06/15/20 Evercore ISI
Dynavax initiated with an Outperform at Evercore ISI
05/19/20 William Blair
William Blair cautious on COVID-driven rally in Dynavax shares
10/18/19 H.C. Wainwright
Dynavax initiated with a Buy at H.C. Wainwright
DVAX Dynavax
$9.37 /

+0.18 (+1.96%)

  • 22
    May
  • 08
    Aug
DVAX Dynavax
$9.37 /

+0.18 (+1.96%)

DVAX Dynavax
$9.37 /

+0.18 (+1.96%)

Hot Stocks
Dynavax announces first patients dosed in Phase 1 trial of Medicago's vaccine » 08:18
07/14/20
07/14
08:18
07/14/20
08:18
DVAX

Dynavax

$8.51 /

-0.15 (-1.73%)

Dynavax Technologies…

Dynavax Technologies announced that the first participants have been dosed in the Phase 1 clinical trial evaluating Medicago's plant-derived vaccine candidate adjuvanted with CpG 1018 to prevent COVID-19. The previously announced collaboration is evaluating the combination of Medicago's Coronavirus Virus-Like Particle with Dynavax's CpG 1018, the adjuvant contained in Dynavax's U.S. FDA-approved adult hepatitis B vaccine. Adding CpG 1018 is intended to enhance the immune response of Medicago's COVID-19 vaccine which may reduce the amount of antigen required per dose, providing more doses to help protect a greater number of people. The study is a Phase 1 randomized, partially-blinded, prime-boost, staggered dose-escalation study intended to assess the safety, tolerability, and immunogenicity of the Coronavirus-Like Particle COVID-19 Vaccine at three dose levels unadjuvanted or adjuvanted with either CpG 1018, or another company's adjuvant, in approximately 180 healthy subjects 18 to 55 years of age, who have been tested for the absence of SARS-CoV-2 antibodies. Preliminary safety and immunogenicity results are expected in October 2020. Medicago is also planning a Phase 2/3 trial to be initiated this October. Medicago's innovative plant-based production platform will be used to manufacture the COVID-19 vaccine antigen. This platform uses plants as mini-factories which create proteins that self-assemble into the virus-like particles that are used in the CoVLP vaccine candidate. Combining Medicago's technology with Dynavax's CpG 1018 adjuvant, the companies expect to be able to deliver up to 100 million doses by the end of 2021. By the end of 2023, Medicago expects to complete the construction of a large-scale manufacturing facility in Quebec City, Canada that Medicago anticipates will have the capacity to produce up to 1 billion vaccine doses annually.

ShowHide Related Items >><<
DVAX Dynavax
$8.51 /

-0.15 (-1.73%)

DVAX Dynavax
$8.51 /

-0.15 (-1.73%)

06/15/20 Evercore ISI
Dynavax initiated with an Outperform at Evercore ISI
05/19/20 William Blair
William Blair cautious on COVID-driven rally in Dynavax shares
10/18/19 H.C. Wainwright
Dynavax initiated with a Buy at H.C. Wainwright
DVAX Dynavax
$8.51 /

-0.15 (-1.73%)

  • 22
    May
  • 08
    Aug
DVAX Dynavax
$8.51 /

-0.15 (-1.73%)

DVAX Dynavax
$8.51 /

-0.15 (-1.73%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.